
First Cancer Patients Treated with Apollon Formularies Products at
The International Cancer and Chronic Pain Institute
· International Cancer and Chronic Pain Institute Officially Opens to Patients
· First cancer patients treated with Apollon's Medical Cannabis Products
· Apollon's Medical Cannabis Products were recently shown to be highly effective in killing cancer cells
· Clinical trials to be performed on Apollon's proprietary Medical Cannabis Products
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
All cancer patients will be treated by experienced specialist physicians with additional expertise in Cannabinoid Medicine, led by Dr Margaret Dingle Spence, an Oncologist and the Medical Director of the International Cancer and Chronic Pain Center in
Apollon's proprietary medical cannabis products were recently shown in pre-clinical 3rd party, independent testing at BIOENSIS laboratories in
In addition to now treating international and local Jamaican patients, the International Cancer and Chronic Pain Institute physicians intend to initiate clinical trials on Apollon's proprietary medical cannabis products through Apollon's CLA license with the approval and oversight of the Ministry of Health and Wellness (MOHW) in
"This is a huge milestone for Apollon", stated Stephen D. Barnhill, MD, Chairman and CEO of Apollon Formularies, plc, "After many years of researching, developing, manufacturing and testing these proprietary Apollon medical cannabis formulations, we are so proud to announce that they are now available to cancer patients by physician prescription at the International Cancer and Chronic Pain Institute".
Dr. Herbert Fritsche, Apollon's Chief Science Officer, and Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of
The establishment of a legal market for medicinal cannabis in
We are very excited to now have these Apollon Products available to cancer patients in
Stephen D. Barnhill, Jr., Chief Operating Officer for
Stene Jacobs, Chief Operating Officer for European and African Operations of Apollon Formularies, commented: "I am delighted to see the progress we have made as a company in
Further Information
On 19 July 2021, Apollon announced that their proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures by direct cytotoxicity.
June 28, 2021, Apollon announced that their proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing triple-negative breast cancer cells in 3D cell culture by direct cell cytotoxicity.
May 18, 2021, Apollon announced that their proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing HER2+ breast cancer cells in 3D cell culture by direct cytotoxicity.
¹ Foreign investment in emerging legal medicinal cannabis markets: the
ENDS
The Directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies
Tel: +44 207 907 9314
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe tim.blythe@blytheweigh.com
Megan Ray megan.ray@blytheweigh.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica, Ltd is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual affiliate of Apollon. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to purchase cannabis under tripartite agreements from licensed cultivators, process, perform research and development, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.